Momenta is a leader in the analysis, characterization, and design of complex pharmaceutical products. Our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure, its manufacturing process and its biological function. These innovative tools enable us to develop complex generics and biosimilars as well as facilitate the discovery of novel medicines. We believe that by applying our innovative technology to our discovery and development programs, we have the potential to create a robust pipeline of innovative generic and novel medicines.
Our success is a result of our committed and talented people. We attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization, process, and biology problems. Using this approach, we have designed tools and methods to understand the structure (characterization of chemical components), structure-process (design and control of manufacturing process) and structure-activity (relationships between structure and biological and clinical activity) of complex mixture drugs. From this knowledge comes a diversified product development pipeline consisting of both generic and novel complex mixture drugs designed to address a variety of medical needs.
In July 2010, Momenta announced the FDA approval of our first drug, Enoxaparin Sodium Injection developed in collaboration with Sandoz. Enoxaparin is a more affordable, generic version of Lovenox® (enoxaparin sodium injection), which is indicated for the prophylaxis of deep vein thrombosis (DVT). Enoxaparin Sodium Injection is a heparin-based complex mixture drug that was developed using our innovative scientific approach. Following this initial success, we are applying a similar approach to developing a generic version of Copaxone® (glatiramer acetate), a complex mixture of polypeptides indicated for the treatment of relapsing-remitting multiple sclerosis. We have also added biosimilars, which are highly similar and potentially interchangeable biologics to our development pipeline. And finally, with the knowledge acquired from our complex generic and biosimilars business, we are our using our tools and technology to design and improve the structures of proteins and heparin-derived products to create novel medicines. Our goal is to leverage the multi-targeting nature of complex mixture molecules to develop novel products which could positively modulate multiple pathways in a disease. Additionally, in December 2011 we acquired selected assets relating to sialylation technology. Sialic acid is a type of sugar modification on selected proteins that is understood to regulate anti-inflammatory and immunomodulatory function. These assets add to our core ability to modify and engineer protein backbones to precisely regulate biological networks and develop novel biologic product candidates.
Lovenox® is a registered trademark of Sanofi-Aventis. Copaxone® is a registered trademark of Teva Pharmaceutical Industries Ltd.
Last revised 10/18/2013